Abiopharma

🔍 Kenneweg John (Executive)

Company: 908 Devices Inc. (MASS)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 26,042 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 83,826.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,787 shares of Common Stock at $6.83 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 76,039.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 26,042 shares of Performance Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each performance stock unit ("PSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
• F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F3: The PSUs vested, in accordance with their terms, on May 1, 2026. The PSUs had no expiration date.